Previous functional magnetic resonance imaging (fMRI) studies examined neural activity responses to emotive stimuli in healthy individuals after acute/subacute administration of antidepressants. We now report the effects of repeated use of the antidepressant clomipramine on fMRI data acquired during presentation of emotion-provoking and neutral stimuli on healthy volunteers. A total of 12 volunteers were evaluated with fMRI after receiving low doses of clomipramine for 4 weeks and again after 4 weeks of washout. Fear-, happiness-, anger-provoking and neutral pictures from the International Affective Picture System (IAPS) were used. Data analysis was performed with statistical parametric mapping (P < 0.05). Paired t-test comparisons for each condition between medicated and unmedicated states showed, to negative valence paradigms, decrease in brain activity in the amygdala when participants were medicated. We also demonstrated, across both positive and negative valence paradigms, consistent decreases in brain activity in the medicated state in the anterior cingulate gyrus and insula. This is the first report of modulatory effects of repeated antidepressant use on the central representation of somatic states in response to emotions of both negative and positive valences in healthy individuals. Also, our results corroborate findings of antidepressantinduced temporolimbic activity changes to emotion-provoking stimuli obtained in studies of subjects treated acutely with such agents.
Introduction
The serotonin (5-HT) and noradrenaline (NA) transmitter systems are critical for the development of normal social behaviour. Their efferent neurons project to several brain regions involved in emotional processing in healthy individuals: the amygdala, the ventral striatum, the orbitofrontal and visual cortical areas (implicated in the evaluation of emotionallysalient stimuli and generation of emotional states), the ventral anterior cingulate cortex (ACC) and the insula (involved in the central mapping of autonomic and visceral reactions associated with emotions), the hippocampus, the dorsal anterior cingulate, and the dorsolateral prefrontal cortices (regulating emotional behaviours) (Phillips, et al., 2003; Critchley, 2005; Phillips, et al., 2008) .
To date, many studies have shown functional abnormalities in the brain regions involved in emotional processing of negative and positive emotionally salient stimuli in unipolar depression (Siegle, 1999; Sheline, et al., 2001; Fu, et al., 2004; Keedwell, et al., 2005a,b; Surguladze, et al., 2005; Schaefer, et al., 2006; Siegle, et al., 2006) . Subjects with unipolar depression have shown normalisation of neural activity after response to antidepressant drugs acting as serotonin (5-HT) reuptake inhibitors (SRIs) and/or NA reuptake inhibitors (NRIs) (Mayberg, et al., 2000; Kennedy, et al., 2001; Fu, et al., 2004; Canli, et al., 2005; Schaefer, et al., 2006) . However, in such studies, the detection of the direct neural mechanism by which SRIs/NRIs mediate their antidepressant effects was confounded by the significant changes in mood, which might influence activity of brain regions involved in emotional processing.
Understanding the effects of 5-HT/NA augmentation upon activity in the above neural system can be facilitated by examining the effect of such medication in healthy individuals without family history of psychiatric disorders. Acute, intravenous administration of an SRI (citalopram) to healthy individuals has been associated with increased recognition of fear and happy facial expressions (Harmer, et al., 2003) , whereas subacute (7-day) oral administration of citalopram or an NRI (reboxetine) has been associated with reduced fear and anger recognition and enhanced positive stimuli recall (Harmer, et al., 2004) . Regarding direct effects upon neural activity, acute administration of the SRI (citalopram) has been associated with increased amplitude of visual-evoked potentials in parieto-occipital areas to pleasant scenes and suppressed responses in frontal and occipital regions to unpleasant scenes (Kemp, et al., 2004) . In addition, in recent functional magnetic resonance imaging (fMRI) studies, acute administration of the SRI (citalopram) has been associated with increased resting activity in amygdala, striatum, thalamus and hippocampus ; with attenuated ventrolateral prefrontal cortical and amygdalar responses to aversive faces , and, in one study, with increased amygdala activity when processing faces (Bigos, et al., 2008) . Acute administration of the SRI (fluvoxamine) has been associated with decreased amygdalar response to aversive compared with neutral stimuli (Takahashi, et al., 2005) . Also, 7-day administration of citalopram has been associated with decreased amygdalar, hippocampal and medial frontal activity to fearful faces (Harmer, et al., 2006) . Similarly, 7-day administration of reboxetine has been shown to provoke reduced amygdalar responses to fear-provoking faces (Norbury, et al., 2007) . These findings suggest that 5-HT/NA reuptake inhibiting antidepressants may attenuate the activity in subcortical limbic neural regions to a higher degree in presence of negative emotional stimuli compared to positive emotional stimuli.
The above findings need to be interpreted in the light of some limitations. First, the studies have not examined neural activity responses to emotive stimuli in healthy individuals after several weeks of sustained 5-HT and/or NA reuptake inhibition, which more closely parallels the clinical uses of antidepressants in unipolar depression and anxiety disorders. Second, previous fMRI studies used paradigms requiring passive viewing or identification of emotion in emotional displays, rather than paradigms that more closely resemble the emotion and cognitive processes involved in social interactions, namely, the appraisal of, and empathic response to, more complex emotionally salient stimuli. The latter paradigms may be more appropriate to examine the putative neural mechanisms mediating antidepressant response.
The present fMRI study sought to compare fMRI data acquired during presentation of emotion-provoking (happiness, fear and anger) and neutral stimuli among healthy volunteers during 4-week administration of the serotonin/noradrenaline reuptake inhibitor clomipramine (medicated status) and after 4-week of clomipramine washout (unmedicated status). We hypothesized that 1) there would be decrease in amygdala activity after repeated clomipramine use in response to negative stimuli; 2) there would be no change or increased neural response in the amygdala after repeated clomipramine use in response to positive stimuli; and 3) repeated clomipramine use would engage other brain regions involved in emotion processing in response to positive and negative stimuli.
Methods

Subjects
A total of 12 healthy individuals [three men and nine women, mean age = 33.5 years (SD = 6.9), mean education = 11.1 years (SD = 0.7)] were selected from a larger sample included in a controlled drug trial conducted at the Institute of Psychiatry of São Paulo, Brazil. This study aimed at investigating whether low doses of clomipramine had an effect on mood improvement in healthy subjects (Gentil, et al., 2007) . Healthy subjects were recruited through newspaper and radio advertisements and were screened by a team of experienced psychiatrists using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (First, et al., 1995) . Subjects did not have a first-degree family history of psychiatric disorders including psychosis, recurrent mood disorders and substance dependence, as assessed by the Family History Screen (Weissman, et al., 2000) . As part of the drug trial, clomipramine was gradually increased according to subject tolerance to up 40 mg/day over 2 weeks and maintained thereafter for an additional period of 2 weeks (mean clomipramine dose 37.5 mg/day; SD = 4.5). Subjects were followed weekly for subjective changes in emotional response to every day stimuli. Side effects (mainly constipation, dry mouth and sexual dysfunction) were present in few subjects and considered mild. No volunteer dropped out due to any of these complaints.
Only subjects showing no subjective mood change to clomipramine (as assessed every week blindly by two psychiatrists) (Gentil, et al., 2007) and who were right-handed according to the Edinburgh Handedness Inventory were included in this study. Exclusion criteria were the following: 1) age greater than 50 years or lower than 21 years at the time of the study; 2) present or past history of neurological and/or general medical conditions, as assessed by non-structured clinical interviewing, physical examination, electrocardiogram and blood/urinary workup;
3) current use of other drugs with psychoactive effects and 4) for female subjects, history of pregnancy or lactation during the past 6 months.
Local ethical committees approved the study and all participants signed a written informed consent form.
Experimental paradigm
We used the following stimuli: 45 pictures from the International Affective Picture System (IAPS) (Lang, et al., 1997) added to three pictures obtained from internet versions of local newspapers, divided in three sets with different emotional content (fear, happiness or anger) and 27 pictures of neutral scenes from the IAPS. The selection of happiness-inducing pictures was restricted to the excited (rather than relaxed) kind to minimise the possibility of major decrements in the level of arousal elicited by happiness-provoking stimuli compared to the fear-and anger-inducing pictures. All pictures were presented via a mirror mounted on the head coil of the fMRI scanner.
Three, 5-min experiments (order counterbalanced across subjects) were carried out during fMRI acquisition, each consisting of a block design paradigm, with five blocks of one type of emotion (fear, anger or happiness) alternated with three blocks of neutral pictures. Before the experiments, subjects were instructed to imagine themselves in the situations while looking at the pictures. Each block comprised three pictures (each presented for 7.5 s, with no inter-stimuli interval), all with the same emotional content (fear, anger, happiness or neutral). The themes for each picture set were the same, involving accidents, natural phenomena, dangerous animals and dentist scenes for the fear blocks; adventure scenes and soccer for the happiness-arousal blocks; observational view of threatening situations or revolting situations for the anger blocks and personal objects and domestic utilities for the neutral blocks. Stimuli presentation was immediately preceded by a statement shown visually on a black background (for 5 s); this strategy was aimed at directing the subject towards experiencing one of the three specific emotions, thus enhancing the desired emotional response. For example, for a block of three fear stimuli including a gun, a thief and a robbery, the instruction was 'you are being robbed'.
After each three-picture set, subjective self-ratings (for fear, anger, happiness and arousal) were obtained over a period of 20 s using discretized scales presented visually, in pseudorandomized order. For each scale, individuals quantified the intensity of the emotional experience as follows: 1) almost nothing, 2) a little, 3) moderate and 4) intense.
To confirm that each set of pictures and its associated cue sentence would elicit the desired emotion in a specific fashion, an off-scanner validation study was carried out previously with 156 undergraduate students (91 men and 65 women) at the same university where the present imaging study was conducted (Tavares, et al, submitted) . A larger pool of pictures were rated using the same four scales cited above. The final sets of three pictures selected for the fMRI study were matched across emotional conditions (happiness, fear or anger) regarding the mean arousal scores and mean intensity of the key emotion obtained in the off-scanner study. Also, the emotionprovoking sets of pictures were matched to the neutral pictures regarding their degree of visual complexity.
Occasions of data acquisition
Each subject participated in the above imaging experiment on two occasions: (1medicated) after a 4-week repeated use of low doses of clomipramine (mean dose 37.5 mg/day) and (2unmedicated) after a 4-week period of washout. A simulated session was performed in the week prior to the medicated state scan using a mock scanner that replicated the MRI environment to habituate each subject to the fMRI procedure. In this mock session, each subject was trained to use the response glove and became used to the paradigm projection, gradient noise and room temperature. During the fMRI session, no subject presented side effects impeditive of successful realisation of the scan.
Image acquisition
Gradient-echo imaging was used to acquire T2*-weighted image volumes using a 1.5-Tesla General Electric Signa LX (Milwaukee, Wisconsin, USA) v8.3 gradient of 23 mT/m, in the Institute of Radiology at the FMUSP. For each of the 152 brain volumes, 25 axial planes parallel to the AC-PC plane were collected with the following parameters: TR: 2500 ms; TE: 40 ms; slice thickness: 5 mm, 0.7 mm gap; FOV: 240 mm and matrix 64 × 64. In addition, a high-resolution threedimensional structural axial SPGR sequence was acquired (TE: 4.2 ms; TI: 400 ms; TR: 10.5 ms; flip angle 15°; FOV: 240 mm; slice thickness: 1.6 mmzero filled to 0.8 mm and matrix: 256 × 256, 232 slices). Image acquisition, stimulus presentation and subjects' response were synchronized via an optical-electrical trigger based on the RF signal used to excite each image slice.
Behavioural data analysis
Planned comparison using paired t-tests were calculated contrasting scale scores between the medicated and unmedicated states for each condition (emotional or neutral pictures) in each of the three paradigms.
Image analysis
Data were pre-processed and analysed using statistical parametric mapping software (SPM5; http://www.fil.ion.ucl. ac.uk/spm, London, UK). Data for each participant were initially realigned using the first brain volume acquired as a reference and unwarped to correct for static inhomogeneity of the magnetic field and movement by inhomogeneity interactions. They were then co-registered with the subjects' structural brain dataset, segmented/normalized to the standard Montreal Neurological Institute template (Ashburner and Friston, 2005) , resampled to 2 × 2 × 2 mm 3 voxels and spatially smoothed with a Gaussian kernel of 6-mm full-width at half-maximum. The time-series in each voxel were high-pass filtered to 1/128 Hz. Images from one subject during the Fear paradigm were not available due to technical problems during data acquisition. The structural dataset was always co-registered with the functional images acquired during the same session.
A single-subject, first-level fixed effect model was constructed with emotion and neutral pictures as separate conditions in a block design, using the period of visual scale presentation and responses as a baseline in the design matrix. Movement parameters from the realignment stage were entered as a covariate of no interest to further control for subject movement. Trials were modelled using the Canonical Haemodynamic Response Function (Friston, 2007) . The two conditions were then entered into the second-level analyses using the relevant t-contrast images (emotional pictures > baseline and neutral pictures > baseline).
A group analysis was conducted on the t-contrasts generated in the previous single-subject analyses using planned comparisons (paired t-test) to compare each condition (either emotional pictures or neutral pictures) at time 1 (medicated state) with the analogous condition in time 2 (unmedicated state). Paired t-testing has been used in previous neuroimaging studies investigating the effect of psychotropic medications on brain functioning (Hariri, et al., 2002; Aizenstein, et al., 2009 ).
Region of interest (ROI) analyses
A priori regions of interest were targeted using anatomical masks created with the Wake Forest University (WFU) Pick Atlas (Maldjian, et al., 2003) . To control for multiple statistical testing, we maintained conservative threshold with a clusterlevel false-positive detection rate at P < 0.05 by using a voxel threshold of P < 0.05 with a cluster (K) extent empirically determined by Monte-Carlo simulations implemented in AlphaSim, which accounted for spatial correlations between BOLD signal changes in neighbouring voxels (Forman, et al., 1995; Gianaros, et al., 2008) . We first accessed neural response in the amygdala. Sequentially, we explored regions involved in emotion processing as follows: ventrolateral prefrontal cortex (vlPFC -BA47), dorsolateral prefrontal cortex (DLPFC -BA9 and 46), ventromedial prefrontal cortex (vmPFC -BA11), dorsomedial prefrontal cortex (mPFCmedial region of BA10), anterior cingulate gyrus (ACG -BA24, 25 and 32), hippocampus, parahippocampal gyrus, insula, caudate, thalamus and putamen. 
Results
Behavioural datasubjective state ratings
There was no significant difference in the mean scores for each scale between medicated and unmedicated states, with the exception of trends towards greater arousal scores in the medicated state during the presentation of neutral pictures in the Happiness and Fear paradigms (P = 0.081 and P = 0.095, respectively), and greater anger scale scores in the medicated state during the presentation of anger-provoking pictures (P = 0.065; Table 1 ).
Functional neuroimaging results
During emotion induction in the Happiness paradigm, ROI paired t-tests did not detect significant activity changes in the right or left amygdala. Exploratory analyses showed significant reductions in brain activity in the right insula, right and left caudate body, right and left ACG (BA24 and 32), right vmPFC (BA11), left mPFC (BA10) and left putamen when subjects were medicated compared to not medicated (Table 2A ; Figure 1 ). There were no statistical increases in the BOLD effect during the Happiness paradigm when we compared the medicated state (clomipramine) with the unmedicated state (washout) using ROI approach. There were no differences in brain activity (at P < 0.05) between the medicated compared to not medicated state during presentation of the neutral pictures.
comparisons, showed decreased activity in the left amygdala when subjects were medicated. We also observed decreased pictures when subjects were medicated. Exploratory analyses showed significant reduction in brain activity in the right and left insulae, right putamen, right parahippocampal gyrus, right thalamus, right and left DLPFC (BA9/46), left vlPFC (BA47), when subjects were medicated compared to not medicated. To neutral pictures, decreased activity was found in the left ACG (BA24) (Table 2B, Figure 1) ; however, an increase in activity was found in the vmPFC (BA11) when subjects were medicated compared to not medicated.
Finally, during emotion induction in the Anger paradigm, paired t-tests comparisons showed reduced activity in the right amygdala. Exploratory analyses showed significant activity reduction when subjects were medicated compared to not medicated in the left and right insulae, right and left thalami, left and right caudate, right and left ACG (BA24/BA32), right and left vlPFC (BA47), right and left DLPFC (BA09/46), left hippocampus, right and left parahippocampal gyrus, right and left putamen (Table 2C, Figure 1 ). To neutral pictures, BOLD signal was reduced in the bilateral insula in the medicated compared to the unmedicated state (Table 2C ).
Discussion
This fMRI study evaluated the neural responses to visually presented emotional stimuli in healthy subjects during 4-week of Clomipramine trial in healthy volunteers using fMRI activity in the right amygdala during visualisation of neutral Emotion induction in the Fear paradigm, using paired t-test repeated use of low doses of clomipramine (mean 37.5 mg/day) and after a 4-week washout period. Healthy subjects had no personal or family history of psychiatric disorders and showed no detectable subjective changes in mood or emotional reactivity to everyday stimuli under repeated use of clomipramine. We were able to replicate previous findings of reduction of amygdala activity after antidepressant use in response to negative stimuli. However, our analysis did not find change in amygdala activity in response to positive stimuli. Although there were some degree of variability in the specific locations of emotionrelated neural activity changes across the three emotionprovoking paradigms used (Happiness, Fear and Anger), we identified a consistent pattern of regionally decreased activity after repeated clomipramine use. The decreased activity occurred in neural regions implicated in the processing of emotional stimuli in healthy individuals, such as the parahippocampal gyrus, anterior cingulate gyrus, insula, subcortical nuclei (striatum and thalamus) and prefrontal cortex (Phillips, et al., 2003 (Phillips, et al., , 2008 . The healthy subjects in the study showed no detectable subjective changes in mood or emotional reactivity to everyday stimuli under repeated use of clomipramine. Thus, the reduced BOLD signal during the medicated state may reflect intrinsic pharmacological effects of clomipramine upon neural activity, rather than improvements in subclinical psychopathology or differences in emotional engagement of the subjects during the processing of visual emotion stimuli between two consecutive scanning sessions. Our findings of decreased activity in amygdala after repeated clomipramine use during the Fear and Anger paradigm parallels previous studies in healthy volunteers. Studies of acute antidepressant use of citalopram showed a decreased amygdala response to aversive faces . Moreover, decreased amygdala response was also demonstrated after acute fluvoxamine use in response to aversive faces (Takahashi, et al., 2005) . Finally, a reduction in amygdala activity after 7-day use of citalopram and reboxetine was demonstrated after fearful faces (Harmer, et al., 2006; Norbury, et al., 2007) . The consistent reduction in the amygdala activity in acute, subacute and repeated antidepressant use is consistent with the idea of antidepressant effects in emotion appraisal rather than regulatory emotion processing mechanisms (Norbury, et al., 2008) . However, one study found increased activation in the amygdala after acute use of citalopram (Bigos, et al., 2008) . The contrasting findings are interesting and need replication. Moreover, studies in unipolar depression groups using sophisticated functional connectivity analysis methods reported increased connectivity between amygdala and subgenual ACC, a regulatory area (Anand, et al., 2007) . Interestingly, we did not find any significant change in the amygdala activity in response to positive stimuli. We might speculate a specific effect of antidepressant in the neural response only after negative stimuli. However, more studies using positive stimuli are necessary to replicate this finding.
Across the three emotion-provoking paradigms, the brain regions with the most significant activity differences between the medicated and the unmedicated state were the anterior cingulate gyrus, putamen and insula. These three regions have been implicated in the brain network critical for the mediation of emotional responses to emotional stimuli (Phillips, et al., 2008; Critchley, 2005) . In particular, the anterior cingulate gyrus and insula areas are believed to be relevant to the cortical mapping of information pertaining to bodily responses that accompany emotional reactions (Drevets, et al., 1997; Craig, 2002; Critchley, 2005) , while the putamen is involved with reward behaviour (Forbes, et al., 2009 ). Furthermore, the anterior cingulate gyrus has been implicated in the generation of changes in autonomic arousal, and the insula is believed to play a key role in the central representation of internal visceral responses during emotional processing (Bechara, et al., 1997) . In addition, the putamen has been implicated in emotional appraisal and identification (Phillips, et al., 2008) . Contemporary theories propose that the central mapping of such emotion-based somatic markers is crucial to the guiding of decisions and behaviours in complex situations, consciously or unconsciously Harmer, et al., 2006; Norbury, et al., 2007) .
Curiously, we found reductions in brain activity in response to negative stimuli (Fear and Anger paradigms) but not to positive stimuli in dorsolateral -and ventrolateral prefrontal cortical regions. These regions are known to be involved with regulation of behaviour and emotion. The use of sophisticated analysis determining the function integration between these regions might help to elucidate the effect of antidepressants in the regulatory process and coupling between the subcortical regions and the prefrontal cortex.
To our knowledge, this is the first study reporting significant activity decrements in the insula and anterior cingulate gyrus in healthy subjects after repeated clomipramine use (4 weeks). Previous fMRI studies on healthy subjects during the presentation of emotion-inducing stimuli have examined the changes in neural activity following only acute (single dose) or subacute (7 days) administration of 5-HT/NA reuptake inhibiting drugs Harmer, et al., 2006; Norbury, et al., 2007; Bigos, et al., 2008; Takahashi, et al., 2005) . Thus, our findings suggest that a sustained 5-HT/NA reuptake inhibition (4 weeks) may induce changes in regions involved in the central representation of emotionrelated autonomic and visceral responses. Because the subjects in the study were selected with exclusion criteria of vulnerability to depressive, anxiety or other mental disorders (they had neither personal nor familiar history of any psychiatric disor-ders), our findings suggest an intrinsic capacity of clomipramine to modify brain activity patterns involved in the normal processing of emotional responses, irrespective of pathological mood features.
Although the duration of clomipramine treatment in this study is close to the latency for antidepressant effects of this drug, the low doses and the absence of anxiety or depressive psychopathology limit the extrapolation of the current findings to clinical states. Nevertheless, one could tentatively take our findings as suggestive that treatment-induced modifications in the processing of emotion-related bodily information are relevant to the mediation of the clinical efficacy of antidepressant drugs. This is consistent with the proposed role of the anterior cingulate gyrus as a surrogate biomarker of antidepressant treatment response, as indicated in previous neuroimaging studies of major depressed patients evaluated before and after antidepressant treatment (Fraguas, et al., 2007) . Moreover, there is evidence that the intensity of autonomic responses during the processing of emotion-provoking stimuli in unmedicated major depressed patients predicts depressive symptom improvement after chronic antidepressant treatment (Fu, et al., 2004) .
It is noteworthy that as other tricyclic antidepressants with serotonin/noradrenaline reuptake inhibitor (SNRI) properties, clomipramine shows high affinity to histaminergic H 1 , α 1adrenergic, 5-HT 2A and muscarinic postsynaptic receptors (Marcourakis, et al., 1993) . Therefore, the differences observed in emotion-related neural activity between medicated and unmedicated states may be due to the effect of clomipramine on one or more of those postsynaptic receptor sites.
The choice of clomipramine for this experiment was based on our group's previous experiments showing that it is clinically effective in doses lower than those usually recommended for major depression, and therefore is likely to decrease unwanted side effects that could mask the more subtle effects on normal mood regulation (Lotufo-Neto, et al., 2001) . Indeed, clomipramine is highly efficacious in relatively low doses in panic disorder (Wijkstra, et al., 2006) Also, its antidepressant efficacy may be higher than that of non-tricyclic antidepressants in severe depression (Gillman, 2007) . Moreover, low doses of clomipramine, such as 10 mg, has been demonstrated to occupy 80% of 5-HT transporter, similar to the occupation pattern of more selective inhibitors in clinical doses (20-40 mg of fluoxetine occupy 80% of the 5-HT transporter) (Wong, et al., 2009) . Finally, pharmacological studies using animal tissue or human cloned receptors have shown that clomipramine shows strong, dual action as both SRI and NRI, fulfilling the criteria of a serotonin/noradrenaline reuptake inhibiting antidepressant even in greater conformity than the more recently marketed agents venlafaxine and duloxetine (Gillman, 2007) .
As we emphasized the detection of any patterns of changes in subjective mood under clomipramine use (and the exclusion from the present report of responders to this drug), we chose to use a fixed scanning order with the first session under the medicated state. Therefore, it is possible that the findings were influenced by non-specific practice effects from the first, chronically medicated, to the second, unmedicated, fMRI session. However, such practice effects are likely to have been minimised because all subjects underwent a simulated scan session one week prior to the medicated assessment. Moreover, previous studies have shown decreased activity in neural regions involved in emotional processing after repeated exposure to emotion-provoking stimuli, rather than the increase in neural activity seen in the post-treatment scan in our subjects. Therefore, the differences in activity in regions implicated in the representation of autonomic states may be related to the direct action of clomipramine, decreasing activity in those neural regions, rather than resulting from practice effects.
Our sample was not balanced in gender distribution and we did not control for possible influence of menstrual cycle phase in our female subsample. Other studies should replicate our finding assessing the menstrual cycle and/or study a larger sample with only women.
In conclusion, the findings of this study indicate that clomipramine, possibly by sustained 5-HT/NA reuptake inhibition, reduces the central representation of somatic states in response to positive and negative emotional stimuli in healthy subjects. Our finding will inform future research on patients with major depression or panic/agoraphobia to clarify the therapeutic effect of antidepressants on neural activity changes in regions involved in the processing of the somatic markers that accompany the generation of emotional states.
